Anticoagulation Medicine in Surgical Repair for Total Anomalous Pulmonary Venous Connection
Total Anomalous Pulmonary Venous Connection
About this trial
This is an interventional treatment trial for Total Anomalous Pulmonary Venous Connection focused on measuring Total anomalous pulmonary venous connection (TAPVC), Anticoagulant management, Pulmonary venous obstruction (PVO), outcomes
Eligibility Criteria
Inclusion Criteria:
- 1. Infants and neonates who are diagnosed with TAPVC
- 2. Infants and neonates who undergo initial surgical repair for TAPVC
Exclusion Criteria:
- 1. Concommitant diagnosis including functional single ventricular, double outlet right ventricle, tricuspid atresia, pulmonary atresia or transposition of the great arteries.
- 2. Older than 1-year-old.
Sites / Locations
- Guangdong Provincial People's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Conventional treatment group
Anti-coagulant treatment
Patients in this group will received conventional treatments. Drug: None. Drug: For the high-risk patients, doctors will assess their risk factors and choose continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) if needed. Aspirin 5 mg/kg may be given every eight hours subsequently for 3 months.
Continuous infusion heparin. Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5mg/kg will be given every eight hours subsequently for three months. Study will follow the intention-to-treat principle.